编者按：6月18日在羊城广州举行的中美乳腺癌高峰论坛上，我们采访到了MD Anderson 癌症中心的外科学教授，前美国临床肿瘤学会（ASCO）行政副主席和CEO----Charles Balch教授。在这次访谈中，他首先分享了今年ASCO大会的一大亮点免疫治疗（Immunotherapy）。在今年的ASCO大会摘要中，有247份摘要与免疫治疗相关，人们对免疫疗法有了更深的理解，对如何更好地运用免疫疗法，从而使病人更为获益等都取得了喜人的进展。
(“The opportunity to do that in a even larger scale is to engage more Chinese doctors in doing clinical trials in the way with the scientific rigor and accuracy that is demanded by the FDA for approval of drugs, or to combine the data from China with those from other institutions. It is going to be very important in having even higher sophistication and accuracy of clean data, and accounting for the variables in patients that we generally use in sophisticated clinical trials.”—Charles Balch)
与此同时他也指出，国际的同行也渴望学习中国的临床经验，因而他以及众多CSCO的领袖认为在中国应该有一本英文的期刊，而Chinese Clinical Oncology杂志正是他们的选择。
What are the highlights of ASCO meeting this year? What insights have you gained from these highlights?
What role do you think the Chinese clinical trials can play in the international arena of fighting against breast cancer?
What are the inner factors that give you such high enthusiasm in scientific writing and publications?
In your career, what is the largest achievement that makes you most proud of yourself?
Charles M. Balch, MD, FACS
Division of Surgical Oncology, Department of Surgery, University of Texas Southwestern Medical Center, Dallas, TX, USA
Dr. Balch leads a distinguished career as a surgical oncologist and authority in melanoma and breast cancer. He has authored over 630 publications on topics such as clinical investigations involving the natural history of melanoma, prognostic factors predicting clinical outcomes, standards of surgical treatment, and the conduct and methodology of clinical research and immunology. He is regarded as one of the leading melanoma experts in the world. He is the editor of Cutaneous Melanoma, regarded as the authoritative textbook on melanoma, now in its 5th edition. He is the founding Editor-in-Chief of the Annals of Surgical Oncology and is Chair of the Melanoma Staging Committee of the American Joint Committee on Cancer, which determines the staging criteria for melanomas worldwide. He has held major leadership roles in clinical research in 3 comprehensive cancer centers (UAB, M D Anderson, and City of Hope). He has been a PI or Co-PI of numerous clinical trials, including 10 phase III trials, most of which were NCI-funded National Phase III trials. He has organized or participated in randomized surgical trials that have defined the current standards of melanoma surgery.